Alzheimer's stem-cell 'success' claims are hard to verify. Small unblinded cohorts report 'stabilisation' or modest gains in 30–50% of patients, but the disease naturally fluctuates and concurrent therapies confound results. Exosome trials often report biomarker shifts without documented cognitive benefit. Realistically, any effect would be slowing of decline in a subset, not restoration of lost memory.
Forty-one registered trials and 9 recruiting studies investigate stem-cell therapy in Alzheimer's. Small cohorts describe modest cognitive-score changes over 6–12 months; most are uncontrolled. Some show shifts in cerebrospinal-fluid or PET amyloid/tau markers, with less consistent functional gains. No trial has prevented decline or shown reversal of neuronal loss. Approved amyloid-targeting antibodies (lecanemab, aducanumab) show modest slowing of early decline — stem-cell benefit is not proven to match them.
Am I a candidate? → · Alzheimer's Disease: full overview → · Alzheimer's Disease cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment